Arkolith/Insider Trading/ZNTL/Form 4

Lackner Mark

Chief Scientific OfficerZentalis Pharmaceuticals, Inc. (ZNTL) · full profile →Form 4 · filed Jan 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$14K
Net Open-Market Flow
-$14K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2025Sell(S)4K$3.12$14K191K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001725160-25-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML